Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Normal Elderly Population Clear all
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Skin Barrier Dysfunction and the Role of Skin Barrier Restoration

NCT03728569
View directory record Official record
Conditions
Cutaneous Inflammation
Interventions
Vanicream Moisturizing Skin Cream, Vanicream Cleansing Soap
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 7, 2026, 4:36 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
82
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Recruiting Phase 2 Interventional

A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

NCT07211685
View directory record Official record
Conditions
Alport Syndrome
Interventions
BAY 3401016, Placebo
Biological · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

NCT00628108
View directory record Official record
Conditions
Allergic Rhinitis, Chronic Urticaria
Interventions
Levocetirizine 1.25 mg, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
6 Months to 11 Months
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

NCT06224348
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
40
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Not listed No phase listed Observational

Relationship Between Vestibular Function and Topographic Memory

NCT01780896
View directory record Official record
Conditions
Normal Elderly Population
Interventions
Not listed
Lead sponsor
Biomedical Development Corporation
Industry
Eligibility
70 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 7, 2026, 4:36 PM EDT
Not listed Phase 2 Interventional

Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants

NCT05865041
View directory record Official record
Conditions
Alopecia Areata
Interventions
Farudodstat, Placebo
Drug
Lead sponsor
ASLAN Pharmaceuticals
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Birmingham, Alabama • Fountain Valley, California • Santa Ana, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

NCT00790400
View directory record Official record
Conditions
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Interventions
Everolimus (RAD001), Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Sep 7, 2026, 4:36 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06130566
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
42
States / cities
Scottsdale, Arizona • Fountain Valley, California • Fremont, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)

NCT06687980
View directory record Official record
Conditions
Lichen Simplex Chronicus
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Anaheim, California • Fremont, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Terminated Not applicable Interventional Results available

A Prospective, Open Label, Multicenter Trial for Evaluating the Efficacy of Treating and Managing Wounds in Elderly Population in Specialized Nursing Facilities Using RD1

NCT04577183
View directory record Official record
Conditions
Diabetic Foot Ulcer, Pressure Ulcer, Venous Leg Ulcer, Trauma Injury, Skin Tear, Chronic Ulcer
Interventions
RD1 System
Device
Lead sponsor
RedDress Ltd.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Butler, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 1, 2024 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

NCT03575871
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Anaheim, California • Los Alamitos, California • Rolling Hills Estates, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study

NCT01729598
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
65 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 7, 2026, 4:36 PM EDT
Completed No phase listed Observational

Assessing Depression in a Geriatric Cancer Population

NCT00580476
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
70 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Comparison of the Metabolic Effects of Fructose, Glucose, High Fructose Corn Syrup and Sucrose at Normal Population Consumed Levels in Adults Aged 20-60 Years Old

NCT01797042
View directory record Official record
Conditions
Obesity
Interventions
Dietary Compliance
Behavioral
Lead sponsor
Rippe Lifestyle Institute
Industry
Eligibility
20 Years to 60 Years
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Sep 7, 2026, 4:36 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

NCT06641076
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Sonelokimab, Placebo
Drug
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Phase 2Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

NCT05523167
View directory record Official record
Conditions
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions
EFG PH20 SC, PBO
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain

NCT02875496
View directory record Official record
Conditions
Early Onset Alzheimer Disease, Mild Cognitive Impairment, Depression, Aging
Interventions
Not listed
Lead sponsor
ElMindA Ltd
Industry
Eligibility
50 Years to 85 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
The Villages, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

NCT04921345
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
2 Years to 12 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
14
States / cities
Fountain Valley, California • San Diego, California • Vista, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)

NCT06687967
View directory record Official record
Conditions
Lichen Simplex Chronicus
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Clarkston, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Terminated Not applicable Interventional

Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population

NCT06544564
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Membrane Wrap™, Standard of Care
Device · Other
Lead sponsor
BioLab Holdings
Industry
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
9
States / cities
Mesa, Arizona • San Franciso, California • DeLand, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Recruiting Phase 3 Interventional

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Sonelokimab, Placebo, Risankizumab
Drug
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
44
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Recruiting Not applicable Interventional

The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population

NCT06428721
View directory record Official record
Conditions
Actinic Keratoses, Aging, Non-Melanoma Skin Cancer
Interventions
Fractionated Laser Resurfacing
Device
Lead sponsor
Wright State University
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 7, 2026, 4:36 PM EDT